#USA #Redwood City #Codexis #ECO Synthesis #Axolabs

Codexis Partners with Axolabs for Oligonucleotide Manufacturing

In a groundbreaking move towards enhancing the production of oligonucleotide therapeutics, Codexis, Inc. (NASDAQ: CDXS), a frontrunner in enzymatic solutions for scalable and efficient therapeutic manufacturing, has entered into a strategic evaluation agreement with Axolabs, a recognized name in the Contract Research Development and Manufacturing organization (CRDMO) sector. This collaboration promises to leverage Codexis’ ECO Synthesis® Manufacturing Platform to revolutionize the production processes of RNA-based drugs.

The partnership was announced on January 7, 2026, and aims to provide Axolabs access to an innovative RNA manufacturing solution driven by enzymatic synthesis — a cutting-edge approach designed to streamline and elevate the manufacturing capabilities for oligonucleotide therapeutics. The agreement not only reflects a significant step towards fostering advanced production technologies but also lays the groundwork for future licensing discussions, potentially promoting broader industry adoption of the ECO Synthesis® platform.

Alison Moore, President and CEO of Codexis, expressed enthusiasm about the agreement, stating, "Part of our mission is to expand the reach of our ECO Synthesis Manufacturing Platform through collaborations with best-in-class CDMOs. Axolabs is an industry-leading CRDMO, and we are delighted to enter into this partnership with them to enable more efficient manufacturing of oligonucleotide therapeutics that address large markets."

Kathleen Campau, Senior Director of Operations for Axolabs, echoed this sentiment, highlighting the significance of this technology in the future landscape of therapeutic oligonucleotide manufacturing. She stated, "This technology has the potential to be pivotal to how therapeutic oligonucleotides are manufactured at scale in the future, enabling more sustainable and cost-effective production. At Axolabs, we are committed to advancing the science behind therapeutic oligonucleotides, and this partnership builds on our long-standing legacy of technology leadership in the field."

The collaboration between Codexis and Axolabs underscores each company’s dedication to excellence and a shared vision of expanding access to high-quality oligonucleotide-based medicines around the globe. With this agreement, both companies are poised to enhance the quality and efficiency of therapeutic oligonucleotide manufacturing, thus promising better healthcare solutions for patients worldwide.

About Codexis, Inc.

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing. Leveraging its proprietary CodeEvolver® technology platform, the company works tirelessly to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes address real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The company is advancing its ECO Synthesis® Manufacturing Platform to facilitate the scaled manufacture of RNAi therapeutics through an enzymatic route. The unique enzymes from Codexis can lead to improvements in yield, energy efficiency, waste reduction, and operational effectiveness in genomic and diagnostic applications. For more information, visit Codexis.

About Axolabs

Axolabs stands at the forefront of nucleic acid therapeutics, driving the design, development, and manufacturing of transformative RNA-based medications. The company provides an end-to-end platform from early discovery to GMP manufacturing, allowing biotech and pharmaceutical partners to expedite the delivery of innovative therapies to patients. With facilities in Kulmbach, Berlin, and Petaluma, Axolabs specializes in various phases of drug development, ensuring comprehensive support. Axolabs is part of the LGC Group. For further details, check Axolabs.